Elicit: Clinical Outcomes of Adalimumab in Rheumatoid Arthritis

Clinical Outcomes of Adalimumab in Rheumatoid Arthritis

Adalimumab achieves sustained clinical effectiveness in rheumatoid arthritis, with 50-60% of patients responding within 12 weeks and two-thirds of long-term persisters maintaining low disease activity or remission over 10 years, while combination therapy with methotrexate and earlier treatment initiation yield superior functional and structural outcomes.

Abstract

Adalimumab demonstrates consistent clinical effectiveness across diverse rheumatoid arthritis populations, with ACR20 responses of 50-60% at 12 weeks and rapid onset of action, as 71% of ultimate responses occur by week 2. Among patients who persist on therapy, 67-71% achieve low disease activity or remission, with benefits sustained over 10 years of treatment. Combination therapy with methotrexate substantially outperforms monotherapy, achieving 80% ACR50 responses at 10 years versus 69% with adalimumab alone, and preventing radiographic progression more effectively (modified total Sharp score change of 4.0 versus 8.8 points). Earlier treatment initiation yields superior outcomes, with patients having disease duration ≤2 years achieving normal function (HAQ-DI <0.5) at rates of 61% versus 40% for those with longer disease duration. Adalimumab remains effective following TNF antagonist failure, with 60% ACR20 responses in this population, particularly among patients who experienced loss of initial response to prior biologics. Safety profiles show serious infection rates of 2.4-2.8 events per 100 patient-years and mortality rates below general population expectations (standardized mortality ratio 0.71-0.75), with no unexpected safety signals during exposures extending beyond 5 years.

Methods

We analyzed 10 sources from an initial pool of 200, using 7 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Records from Elicit search

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex. We ran this query: “Clinical outcomes rheumatoid arthritis adalimumab”. The search returned 200 total results from Elicit. We retrieved 200 papers most relevant to the query for screening.

Screening

We screened in sources based on their abstracts that met these criteria:

Data extraction

We asked a large language model to extract each data column below from each paper.

Patient Population:

Adalimumab Treatment:

Clinical Outcome Measures:

Clinical Effectiveness Results:

Safety Outcomes:

Quality of Life:

Outcome Moderators:

Study Design:

Results

Characteristics of Included Studies

The review included 10 studies evaluating adalimumab in rheumatoid arthritis patients, with study durations ranging from 12 weeks to 10 years. Full text was available for 6 studies, while 4 were analyzed based on abstracts only.

Study Full text retrieved? Study Type Patient Population Disease Duration Baseline Disease Activity Treatment Regimen Duration Setting
V. Strand et al., 2012 Yes Phase III RCT, double-blind MTX-naive early RA Mean 9 months ≥8 swollen joints Adalimumab 40mg EOW ± MTX 104 weeks Clinical trial, 133 sites in North America, Europe, Australia
B. Haraoui et al., 2011 Yes Multicenter, open-label, prospective Active RA, 97.8% prior DMARD experience Mean >12 years Mean DAS28 6.1 Adalimumab 40mg EOW + prior DMARDs 12 weeks Real-world, 69 sites across Canada
S. Bombardieri et al., 2007 No Open-label trial Prior TNF antagonist exposure Not mentioned Not mentioned Adalimumab 40mg EOW 12 weeks Clinical trial
D. Pappas et al., 2017 Yes Observational registry Biologic-naive adults with RA Mean 7 years Mean CDAI 19.9 Not specified Up to 12 years Real-world, 170 sites across 40 US states
G. Burmester et al., 2014 Yes Phase 3b + postmarketing observational Active RA, failed ≥1 DMARD Not mentioned Mean DAS28 6.0 Adalimumab monotherapy or + DMARDs Mean 1,016 days (5+ years) Real-world, 10 European countries and Australia
L. B. A. Putte et al., 2003 No Phase II RCT, double-blind, placebo-controlled DMARD-refractory, longstanding active RA Longstanding Not mentioned Adalimumab 20/40/80mg weekly monotherapy 12 weeks Clinical trial
A. E. van der Bijl et al., 2008 Yes Prospective open-label pilot Active RA, prior infliximab failure Mean 12 years DAS28 ≥3.2 Adalimumab 40mg EOW + existing DMARDs 16 weeks, maintenance to 56 weeks Clinical trial
E. Keystone et al., 2014 Yes RCT with open-label extension (PREMIER OLE) Early RA, disease duration <3 years <3 years DAS28 5.6 ± 1.7 Initial: adalimumab 40mg EOW ± MTX; OLE: adalimumab with optional MTX 2 years DB + 8 years OLE Clinical trial, Australia, Europe, North America
D. Karateev et al., 2012 No Open-labeled multicenter Active RA unresponsive to standard therapy Not mentioned DAS28-CRP 6.2 ± 0.84 Adalimumab 40mg EOW + DMARDs 24 weeks Clinical trial, Russia
D. Furst et al., 2015 No Phase 3 open-label extension (DE020) DMARD-refractory RA Mean 11.7 years Not mentioned Adalimumab 40mg EOW or monthly Up to 10 years Clinical trial continuation

Clinical Effectiveness

Disease Activity and Response Rates

Clinical effectiveness varied by study duration and population characteristics. In short-term studies (12-24 weeks), ACR20 response rates ranged from 37% at 4 weeks to 88% at 24 weeks. At 12 weeks, ACR20 responses were achieved by 50.7-60% of patients, ACR50 by 27-33%, and ACR70 by 8-13%. Long-term studies demonstrated sustained or improved response rates.

Remission and Low Disease Activity

Remission rates varied by definition and study duration. Low disease activity (DAS28 <3.2) and remission rates improved significantly at various points, indicating the effectiveness of the treatment.

Functional Outcomes

Functional status improved across studies, measured primarily by HAQ-DI. Significant improvements were noted across different studies, suggesting the benefits of treatment over time.

Radiographic Progression

Long-term studies showed meaningful benefits in radiographic measures, with significantly less progression occurring in patients receiving combination therapy.

Clinical Outcomes in Special Populations

Adalimumab showed clinical benefits among patients with prior TNF antagonist failures, achieving notable response rates.

Safety Outcomes

Safety data were reported across varying durations of exposure, showing manageable rates of adverse events and serious infections.

Patient-Reported Outcomes and Quality of Life

Health-related quality of life measures showed significant improvements across studies, indicating the treatment's positive impact on patients' daily lives.

Factors Influencing Treatment Effectiveness

Disease Duration and Timing of Treatment

Earlier treatment initiation consistently predicted better outcomes.

Combination Therapy Versus Monotherapy

Combination therapy with methotrexate consistently outperformed monotherapy across multiple measures.

Prior Biologic Exposure

Prior biologic exposure influenced treatment responses, with substantial benefits still observed following TNF antagonist failure.

Baseline Disease Severity

Baseline disease severity influenced outcomes, showing better responses in patients with milder disease at initiation.

Methodological Quality and Real-World Effectiveness

The convergence of findings from randomized controlled trials and real-world observational studies strengthens confidence in effectiveness estimates.

References

  1. S. Bombardieri et al. (2007)
  2. D. Pappas et al. (2017)
  3. G. Burmester et al. (2014)
  4. V. Strand et al. (2012)
  5. B. Haraoui et al. (2011)
  6. L. B. A. Putte et al. (2003)
  7. A. E. van der Bijl et al. (2008)
  8. E. Keystone et al. (2014)
  9. D. Karateev et al. (2012)
  10. D. Furst et al. (2015)